Global oncology firm BeOne Medicines (ONC) has Wall Street analysts forecasting 177% earnings growth for the year. That has BeOne stock popping into a fresh buy zone. The biotech also earns a near-ideal 98 Composite Rating, putting in the top 2% of all stocks in terms of key stock-picking factors. That puts BeOne alongside Halozyme Therapeutics (HALO), Exelixis (EXEL) and…